Bio-Thera Solutions

Bio-Thera reports positive data from solid tumors therapy trial
Clinical Trials Arena
Mon, 08/14/23 - 10:11 am
Bio-Thera Solutions
solid tumors
clinical trials
BAT8006
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
Wed, 05/31/23 - 10:51 am
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Biopharma developments over the Christmas period
EP Vantage
Mon, 01/3/22 - 10:26 am
Alnylam Pharmaceuticals
Bio-Thera Solutions
BioArctic
Biogen
BridgeBio Pharma
Daiichi Sankyo
Eisai
JNJ
Madrigal Pharmaceuticals
Merck
Sutro BioPharma
Tasly Pharmaceutical Group
Sandoz in oncology biosimilar deal with China’s Bio-Thera
Biopharma Reporter
Wed, 09/8/21 - 11:15 am
Sandoz
Novartis
biosimilars
China
BAT1706
Bio-Thera Solutions
Bio-Thera Solutions announces positive top-line results for BAT1706, a proposed biosimilar to Avastin
Pharmaceutical Business Review
Tue, 02/4/20 - 10:05 am
BAT1706
Bio-Thera Solutions
Avastin
Roche
non-squamous non-small cell lung cancer
biosimilars
Chinese Biotech Bio-Thera Solutions Initiates Ph III Trial of HER2 ADC in Metastatic Breast Cancer
CP Wire
Thu, 11/1/18 - 10:29 am
Bio-Thera Solutions
HER2-positive metastatic breast cancer
BAT8001
China
Chinese Biotech Bio-Thera Solutions Initiates Ph III Trial of HER2 ADC in Metastatic Breast Cancer
Thu, 11/1/18 - 09:52 am
Bio-Thera Solutions
HER2-positive metastatic breast cancer
BAT8001